DSIP (Delta Sleep-Inducing Peptide) — Clinical Reference

**⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article. ## Introduction Delta Sleep-Inducing Peptide (DSIP) is a nine-amino-acid neuropeptide isolated by the Schoenenberger–Monnier group in the 1970s during studies of slow-wave-sleep-inducing factors. Investigational; no approved clinical indication exists in the United States. ## Mechanism of Action Receptor mechanism is incompletely characterized. DSIP appears to modulate CRH signaling, blunt HPA-axis activation, and influence GABAergic and opioidergic tone. The compound is reported to act centrally despite limited classical blood-brain-barrier penetration. ## Research Indications Research contexts include disordered sleep architecture, chronic pain, withdrawal syndromes, and stress-related conditions. Published human data are limited in volume and methodological rigor. ## Reconstitution Typical 5 mg lyophilized vial: add **2.5 mL of bacteriostatic water**, swirl gently until clear. Final concentration **2000 mcg/mL (2 mg/mL)** — each 0.05 mL (5 units on a U-100 insulin syringe) delivers 100 mcg. ## Dosing Protocol (research literature) Research protocols typically dose **100–500 mcg subcutaneously once daily**, administered **30–60 minutes before sleep**. Most cited duration: **2–6 weeks** continuous, followed by reassessment. Some protocols cycle 5 days on / 2 days off. ## Administration Subcutaneous injection into abdominal fat, rotating sites. Evening timing aligns with the intended sleep-architecture effect. ## Storage & Handling Lyophilized: refrigerate (2–8°C). Reconstituted: refrigerate; stable approximately **14–21 days**. Protect from light. Do not freeze. ## Side Effects Reported in available studies: mild injection-site discomfort, occasional headache, vivid dreaming. Generally well-tolerated in published reports. ## Contraindications Pregnancy, lactation, untreated mood disorders, and concurrent CNS-depressant regimens without clinician supervision. ## Monitoring Validated sleep instruments (PSQI, ISI) at baseline and 4–6 weeks. Where insomnia is the indication, address sleep hygiene, caffeine timing, and screening for obstructive sleep apnea before attributing improvement or non-response to the peptide. ## Disclaimer **This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation. **Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make. The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.